The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line...

por Swallow, Elyse, Messali, Andrew, Ghate, Sameer, McDonald, Evangeline, Duchesneau, Emilie, Perez, Jose Ricardo
Publicado 2018